

## A Comparative clinical study to evaluate the effect of Indigenous compound drugs (*Shatavari mandoor* and *Pippali ghrta*) in *Parinama Shoola* Vis-à-vis Acid Peptic Disorders

### Research Article

Pragya Singhal<sup>1\*</sup>

1. Clinical Registrar/ Asst. Professor (Kayachikitsa),  
Ch. Brahm Prakash Ayurved Charak Sansthan, Khera Dabar, Najafgarh, New Delhi

### Abstract

**Background:** : Acid peptic disease is the condition in which there is either excessive secretion of acid and pepsin or a weakened stomach mucosal defence, which is responsible for damage to the delicate mucosa and the lining of the stomach, oesophagus and duodenum resulting in ulceration. *Parinama shoola* in Ayurveda is comparable with Acid peptic disease.

**Aim of study:** The Aim of the study is to evaluate and compare the effect of indigenous compound drugs (*Shatavari mandoor* and *Pippali ghrta*) in uncomplicated cases of *Parinam shoola*.

**Methods:** This is a prospective, open labelled, randomised clinical trial. A total of 31 patients suggestive of features of *Parinama Shoola* (acid peptic disorder) were enrolled and were randomly divided in two groups- 12 patients were enrolled in group A and were given trial drug *Shatavari mandoor*, 19 patients were enrolled in group B and were given trial drug *Pippali ghrta*. Duration of study was 3 months.

**Results:** Individually both groups showed statistically significant improvement in clinical symptoms i.e. pain in abdomen, epigastric burning, nausea, flatulence, loss of appetite and constipation ( $p < 0.01$ ), but the mean reduction in the symptoms of group A (*Shatavari mandoor* group) is more than group B (*Pippali ghrta* group).

**Conclusion:** Both trial drugs are effective in the treatment of *Parinama shoola*. *Shatavari mandoor* is more effective in the treatment of *Parinam shoola* in comparison to *Pippali ghrta*.

**Keywords:** Acid peptic disorder, epigastric pain, *Parinama shoola*, Peptic ulcer disease

### Introduction:

An ulcer is defined as disruption of mucosal integrity of stomach and or duodenum leading to local defect or excavation due to active inflammation.

Peptic ulcers are estimated to occur in 6-15% of general population. The incidence of peptic ulcer declined steadily from 1960-1980 and then remained stable since then. (1)

The cardinal feature of peptic ulcer disease is epigastric pain which is characterised by gnawing or burning, may be ill defined, may be aggravated by meals or relieved few minutes after meals. Other associated symptoms include nausea, vomiting, flatulence, abdominal distension, water brash etc.

In Ayurveda, *Parinama shoola* is a disease in which abdominal pain during digestion is observed. The

aetiology, pathogenesis and clinical manifestation of *Parinama shoola* have got a striking similarity with acid peptic disorders in modern medicine.

The disease *Parinama shoola* was first mentioned by Madhavakara. In the aetio pathogenesis of *Parinama shoola* Madhavakar has given much importance to *vata* (2) in causing the disease, whereas Vijay rakshita in explaining the disease gave a specific and scientific pathogenesis of *Parinama shoola*. According to Vijay rakshita, *Parinama shoola* is a disease of *tridosha*, *pitta* predominance is present as the pain occurs during the period of digestion. (2)

In *Parinama shoola* abdominal pain occurs at the phase of digestion. '**Bhukte Jeeryati yata Shoolam Tadeva Parinamajam**' (3)

Three *dosas* i.e. *vata*, *pitta* and *kapha* are involved in the pathogenesis of *Parinama shoola*. In all types of *shoola* (pain), *vayu* is the predominant causative *dosha* which is correlated with sympathetic nervous mechanism of sensation of pain in the abdominal visceral organ. *Kapha* refers to the *kledaka kapha* which has parlance with mucus gel layer and mucin of modern medicine. So *kapha* is for defensive mechanism in the pathogenesis of *Parinama shoola*. *Pitta* is related with HCL and pepsin and it is for aggressive mechanism causative for *Parinama shoola*.

\*Corresponding Author:

**Pragya Singhal**

Clinical Registrar/Assistant Professor (Kayachikitsa)

Ch. Brahm Prakash Ayurved Charak Sansthan,

Khera Dabar, Najafgarh

New Delhi

Mobile No.: +91-9999984610

E-mail: [pragyasinghalagarwal@gmail.com](mailto:pragyasinghalagarwal@gmail.com)

**Clinical study to evaluate the effect of indigenous compound drugs in Parinama Shoola**

Two trial drugs, *Shatavari mandoor* and *Pippali ghrita* were selected for the present study.

Many previous studies (clinical and experimental) regarding the antiulcer effect of *Shatavari mandoor* were done, which showed promising results in cases of acid peptic disorders. (4,5)

*Pippali ghrita* has been described in *Chakra dutta* in the context of *Parinama shoola*. According to Chakra dutta, *Pippali ghrita* has been able to treat complicated cases of *Parinama shoola*. (6) and thus it was assumed that *Pippali Ghrita* would be beneficial in patients of *Parinama Shoola*.

This study revealed the effect of herbomineral drugs (*Shatavari mandoor* & *Pippali ghrita*) in the treatment of *Parinama shoola*.

**Material & Methods**

**Study design:** It is a prospective, randomised, open labelled, parallel designed, clinical study.

**Inclusion criteria**

Patients showing clinical signs and symptoms suggestive of *Parinama shoola* like pain in epigastric pain, heartburn, acid eructation, water brash etc. Subjects above 20 years and below 60 years

**Exclusion criteria**

- Pregnant and lactating mothers
- Patients having gall bladder disease, worm infestation, cardiovascular and liver disorders.
- Malignant and complicated ulcers

**Grouping of patients**

Patients were randomly divided into two groups  
 Group A: 12 Patients were included in group A and were administered with trial drug *Shatavari mandoor*.  
 Group B: 19 Patients were included in group B and were administered with trial drug *Pippali ghrita*.

**Criteria of assessment**

Clinical signs and symptoms: *Udarasula* (pain in abdomen), *utklesa* (feeling of nausea and vomiting), *aruci* (loss of appetite), *hritkanthadaha* (heart burn) etc. were assessed before and after the treatment. Clinical assessment was made by grading as 0,1,2,3 on the basis of severity.

**Grading pattern for signs and symptoms**

**Udar shoola** (epigastric pain)

- Grade-0: No Pain
- Grade-1: Mild pain
- Grade-2: Moderate pain
- Grade-3: Severe pain

**Hrikantha daha** (burning in epigastric region)

- Grade-0: No Heart burn
- Grade-1: Occasional retrosternal burning
- Grade-2: Retrosternal burning 1-2 times; relieved by

- food or antacids
- Grade-3: Frequent retrosternal burning

**Utklesh** (nausea)

- Grade-0: Absent nausea
- Grade-1: Occasional desire to vomit
- Grade-2: Frequent desire to vomit
- Grade-3: Regular desire to vomit

**Adhmaan** (flatulence)

- Grade-0: Absent feeling of gaseous distension
- Grade-1: Occasional feeling of gaseous distension
- Grade-2: Frequent feeling of gaseous Distension

**Aruchi** (loss of appetite)

- Grade-0: Normal appetite
- Grade-1: Mild loss of appetite
- Grade-2: Moderate loss of appetite
- Grade-3 Severe loss of appetite

**Praseka** (water brash)

- Grade-0: No complaint of water brash
- Grade-1: Occasional feeling of water
- Grade-2: Frequent complaint of watery mouth
- Grade-3: Regular complaint of watery mouth

**Treatment Protocol**

**Trial Drugs**

**Table 1: Ingredients of trial drugs** (all the parts of ingredients were taken by weight)

**Shatavari Mandoor (7)**

<i>Shatavari swarasa</i>	2 parts
<i>Mandur churna</i>	2 parts
<i>Godugdha</i>	2 parts
<i>Godadhi</i>	1 parts
<i>Go Ghrita</i>	1 parts

**Pippali Ghrita (6)**

<i>Pippali Kawatha</i>	4 parts
<i>Pippali Kalka</i>	1 part
<i>Go Ghrita</i>	1 part

**Method of preparation of trial drugs**

**Method of preparation of Shatavari mandoor**

Two parts of *Mandoor bhasma*, two parts of fresh juice of *Shatavari swaras*, two parts of cow's curd and milk and one part of cow's ghee were mixed and heated at low temp till the water content is evaporated and whole material becomes dry.

Dose: 1.5 gm. Bid

Mode of administration: Patients were advised to take the drug twice daily along with the meal. Drug is divided approximately into three parts, which should be taken in

the first, middle and last bolus of the food.

**Method of preparation of Pippali ghrta**

Four parts of *Pippali kawatha*, one part of *Pippali kalka* and one part of *Go ghrta* are mixed together and heated till *ghrita* is prepared

Dose: 5 gm. Bid

Anupana : *Sukoshana dugdha* (Luke warm milk)

**Follow up:**

Total duration of treatment was 3 months. The symptoms and signs of patients were recorded in detail once in a month before and during the treatment.

**Statistical analysis**

The data obtained in clinical studies before and after treatment was expressed in terms of mean, standard deviation. Appropriate t’ test was applied to test the significance of comparative mean values of before and after treatment.

**Observation and results**

The study of demographic profile displayed that *Parinama shoola* was more prevalent among males (60%), between the age group of 20-50 years, most of the patients belong to rural areas (63.3%), having spicy dietary habit (37%) and *vata-pitta deha prakriti* (43.6%), the *sharad ritu* (33.3%) and *rajasika manas prakriti* (66.6%), 20% of the patients were having anxiety and 13% of patients were having depression in the study. Regarding addiction (6.67%) were addicted to smoking (23.3%) to tobacco chewing and (3.33%) to consumption to alcohol. [Table 2]

Most common symptoms observed were *udar shoola* (epigastric pain), *hrikantha daha* (burning in epigastric region), *utklesh* (nausea), *adhmaan* (flatulence) along with these, *aruchi* (loss of appetite), *vibandha* (constipation) and *praseka* (water brash) were also present in the patients of *Parinama shoola*.

In Group A significant improvement was observed in epigastric pain (p<0.001), heart burn (p<0.01), loss of appetite (p<0.01), water brash (p<0.02), flatulence (p<0.02), constipation, (p<0.02), nausea (p<0.01). [Table-3].

In Group B significant improvement was observed in epigastric pain (p<0.001), heart burn (p<0.001), loss of appetite (p<0.01), water brash (p<0.05), flatulence (p<0.01), constipation, (p<0.001), nausea (p<0.01). [Table-3]

**Table 2: Demographic profile**

Observations	Percentage
<b>Age</b> 20 years-50 years	86.6
<b>Sex</b> Male Female	60 40

Observations	Percentage
<b>Habitat</b> Rural Urban	63.33 36.66
<b>Addiction</b> Tobacco Smoking Alcohol	23.33 6.67 3.33
<b>Deha prakruti</b> <i>Vataja</i> <i>Pittaja</i> <i>Vāta-paittika</i>	18.33 21.66 43.66
<b>Manasa Prikriti</b> <i>Rajas</i> <i>Tamas</i>	66.6 33.3
<b>Psyche phenomenon</b> Anxiety Depression	20 13.33
<b>Dietary habits</b> Spicy food	37
<b>Kala</b> <i>Sarad ritu</i> <i>Hemanta ritu</i> <i>Vasanta ritu</i>	33.3 23.3 16.6

**Table 3: Effect of treatment on clinical sign and symptoms**

Clinical signs & symptoms	Gro up	BT Mean ± SD	AT Mean ± SD	T	P
<i>Udarasu-la</i>	A	2.58 ±0.51	0.75 ±0.45	11.0	P<0.001
	B	2.58 ±0.51	1.74 ±0.45	9.8	p<0.001
<i>Aruchi</i>	A	1.33 ±0.98	0.42 ±0.51	4.0	p<0.01
	B	1.05 ±1.18	0.58 ±0.69	3.37	p<0.01
<i>Utklesa</i>	A	1.08 ±1.00	0.42 ±0.67	4.69	p<0.01
	B	1.37 ±0.90	0.95 ±0.71	3.62	p<0.01
<i>Hritkan-thadaha</i>	A	1.83 ±0.94	0.92 ±0.67	4.75	p<0.001
	B	1.89 ±0.81	1.26 ±0.69	5.53	p<0.001
<i>Adhmana</i>	A	0.75 ±0.62	0.33 ±0.49	2.80	p<0.02
	B	1.21 ±0.79	0.74 ±0.56	2.96	p<0.001
<i>Praseka</i>	A	0.83 ±0.83	0.42 ±0.51	2.80	P<0.02
	B	0.42 ±0.77	0.21 ±0.45	2.14	p<0.05
<i>Vibandha</i>	A	1.17 ±1.03	0.58 ±0.67	3.02	p<0.02
	B	1.21 ±0.71	0.58 ±0.51	5.55	p<0.001

**Clinical study to evaluate the effect of indigenous compound drugs in Parinama Shoola****Discussion:**

Acid peptic disorder becomes a significant problem in the medical world because of its higher incidence, incomplete aetio-pathogenesis, relapse and severe consequences. In spite of phenomenal process in H. pylori researches a great relapses in APD are found. A relative failure of modern medicine has made the majority of population to turn towards alternative system of medicine.

In the present study regarding age, high incidence was observed in between 2<sup>nd</sup>, 3<sup>rd</sup> and 4<sup>th</sup> decade of age group which may be due to pitta predominance in this age. In this study males were 60% and 40% were females. Thus it appears the disease of male predominance.

Vata-pitta trait of *deha prakriti* (43.33%) and *rajasika* type of *manasa prikriti* (63.33%) persons are more prone to acid-peptic –diseases. Thus suggesting that *Parinama shoola* is a vata-pitta predominant disease.

Certainly, the influence of *kala* (season) is present in *Parinamashoola*. It has been indicated in this study in the form of high incidence (33.33%) of the disease in patients during *Sharad ritu* (autumn season). *Sharad ritu* has been considered as the *pitta prakopaka kala*, thus the incidence of the disease in this *kala* suggests the prominence of *pitta* in *Parinama shool*.

Observations regarding dietary habits showed that people who used to take spicy diet were more prone to develop this disease than those patients who were taking ordinary diet, thus suggesting that *pitta prakopaka ahara* (aggravating diet) aggravates the disease, indicating that *Parinama shoola* is a *pitta* predominant disease.

Statistical data revealed that the trial drugs showed statistically significant improvement in *udar sholoa*, *aruchi*, *utklesha*, *hritkantha daha*, *adhmana*, *vibandha*, and *praseka* ( $p < 0.01$ )

In *udarshoola* (epigastric pain), both the trial drugs showed statistically highly significant improvement ( $p < 0.001$ ), but the mean decrease in the intensity of epigastric pain of group B was found lesser as compared to group A, which suggested that trial drug *Shatavari mandoor* is more effective in improving epigastric pain in comparison to *Pippali ghritha* in patients of *Parinama shoola*.

Similarly, both the trial drugs also showed statistically significant improvement ( $p < 0.001$ ) in *hrit kantha daha* (epigastric burning), but the mean decrease in this symptom in group A was more in comparison to group B, thus indicating that *Shatavari mandoor* is having more *pitta shamak* action in comparison to *Pippali ghritha*.

Statistical data revealed that, constipation is significantly reduced in both groups at the end of the treatment but highly significant improvement was observed in group B ( $p < 0.001$ ). Also, group B showed highly significant improvement in flatulence ( $p < 0.001$ ) in comparison to group A ( $p < 0.01$ ), thus indicating the

*vata shamak* action of *Pippali ghritha*.

**Mode of action of trial drugs:**

Trial drug *Shatavari mandoor* is a herbomineral compound which consists of *Mandoor bhasma*, *Shatavari swaras*, *Goghrit*, *Godugha*, and *Gavya dahi*. (7)

Pharmacological properties of *Shatavari* (*Asparagus racemosus*) are *madhur tikta rasa*, *pichala-snigdha guna*, *sheeta veerya* and *madhur vipaka* (8).

Several clinical studies showed the antiulcer effect of *Shatavari*. (9,10)

*Mandoor* is *kashaya* in *rasa*, *sheeta*, *guru*, *pitta shamak* in *guna* (property). *Go dudha* and *Go ghritha* are *sheeta*, *madhur* and *vata-pitta nashaka*.

These properties of *Shatavari Mandoor* helps in pacification of *pitta* and *vata*, (7) which are the main aggravating factors in the pathogenesis of *Parinama shoola*.

Also several clinical studies regarding the antiulcer properties of *Shatavari mandoor* have been conducted and revealed its antiulcer effect owing to strengthen mucosal defence mechanism in acid peptic disorders. (4,5)

Second trial drug is *Pippali ghritha* which consists of *Pippali kawatha*, *Pippali kalka*, *Go ghritha*. (6)

*Pippai* (*Piper longum*) is *katu rasa pradhan*, *snigdha* and *ushna* in *guna* (property) and *vatanulomak* in action. (11)

*Pippali* can act as *vatanulomak* (pacifies abdominal gases) and *shoola prashmak* due to its *snigdha –ushna guna*, *agni deepan* (improving digestive fire) due to *katu rasa*. *Ghritha* is having the property of *vata- pittahara*, *shoola-prasamana* (pain relieving), *snehana*, *agnideepan* (improving digestive fire). *Ghritha* has also been claimed a good *vranaropak*. (ulcer protective property). Thus drug may act as cytoprotective (barrier of acid-pepsin in the epithelial lining of stomach, duodenum) in the patients of *Parinama shoola*.

An experimental study, has also showed antiulcer effect of *Piper longum* in rats. (12)

Thus, the antiulcer property of the trial drugs *Shatavari Mandoor* and *Pippali ghritha*, is probably owing to their cytoprotective, *shoola prashmak* and *vatanulomaka* action.

**Conclusion:**

This is evident from both clinical and statistical improvement that the drugs *Shatavari mandoor* and *Pippali ghritha* are effective in the treatment of *Parinama shoola* and their ulcer protective effect may be through promotion of defensive mucosal mechanism rather than affecting the offensive acid-pepsin secretion.

It was observed that, *Shatavari mandoor* is more effective in relieving symptoms like burning sensation whereas *Pippali ghritha* is more effective in relieving symptoms like flatulence and constipation in patients of



*Parinaam shoola.*

Thus, it can be concluded from the present study that *Pippali ghrita* would be effective in vata predominant *Parinaam shoola* and *Shatavari mandoor* would be effective in pitta predominant *Parinaam shoola*.

**References:**

1. Harrison's Principle of Internal medicine. 16<sup>th</sup> Edition Vol. 2. Peptic ulcer disease and related disorders.
2. Madhavkar, Madhav Nidan with Madhukosha Sanskrit commentary by Vijay Rakshita, Srikanta Dutta, Hindi commentary by Brahm Shankar Shastri. Chapter 26 Verse 15. Varanasi. Chaukhambha Sanskrit Sansthan; Reprint 2012. Page 183.
3. Madhavkar, Madhav Nidan with Madhukosha Sanskrit commentary by Vijay Rakshita, Srikanta Dutta, Hindi commentary by Brahm Shankar Shastri. Chapter 26 Verse 16. Varanasi. Chaukhambha Sanskrit Sansthan; Reprint 2012. Page 183.
4. Sailaja and Tiwari SK. A Clinical study / biochemical study in treatment of Parinama shoola vis-à-vis acid peptic disorder with Shatavari Mandoor. MD Thesis, BHU. Varanasi. 2000.
5. Prasanna Lakshmi NC, Tiwari SK. A Clinical study in treatment of Parinama shoola vis-à-vis acid peptic disorder with Shatavari Mandoor. MD Thesis, BHU. Varanasi. 1999.
6. Chakrapani, Chakradatta. Commentry by Ravidutt Shastri. Parinama Shoola Rogadhikar. Chapter 27. Verse-25. Varanasi. Chaukhambha Subharti Prakashan. Reprint 2006. Page 127.
7. Chakrapani's Chakradatta. Commentry by Ravidutt Shastri. Parinama Shoola Rogadhikar. Chapter 27. Verse-34,35, 36. Varanasi. Chaukhambha Subharti Prakashan. Reprint 2006. Page 128.
8. Bhavmishra's Bhavprakash Nighantu. Commentry by KC Chunekar. Edited by GS Pandey. Guduchiyadi verga. verse 186-187. Varanasi. Chaukhambha Bharti Academy. Reprint 2010. Page No 378.
9. Maheshwari C M, Chaturvedi GN. Clinical correlation of Parinama shoola and its treatment with indigenous drug Shatavari. MD Thesis, BHU. Varanasi. (1977)
10. Singh KP, Singh RH. Clinical trial on Shatavari in Peptic ulcer. Journal of Research in Ayurveda and Siddha. 1986. Vol. 3(3-4). P 91-100.
11. Bhavmishra's Bhavprakash nighantu. Commentry by KC Chunekar, edited by GS Pandey. Haritkayadi verga. verse 54. Varanasi. Chaukhambha Bharti Academy. Reprint 2010. Page 15.
12. Agarwal AK, Sairam M, Rao V, Goel RK. Effect of Piper longum Linn, Zingiber officinalis Linn, and Ferula species on gastric ulceration and secretion in rats. Indian Journal of Experimental Biology. Oct 2000. Vol. 38. P994-998.

\*\*\*\*\*